MindWalk Holdings Corp., a Bio-Native AI company, unveiled the first public demonstration of ReefIQ, its biological context layer for AI drug discovery, running on AMD Instinct at AMD’s Advancing AI 2026 in San Francisco. MindWalk is featured in the AMD Instinct Demo Showcase, appearing in one of four custom demo vignettes, with an accompanying video interview distributed through AMD’s channels.
The demonstration is the first time MindWalk has shown ReefIQ publicly in action. It walks through how ReefIQ reconnects fragmented discovery data into governed, queryable biological context, then lets AI models and agents reason over that context, running on open AMD Instinct compute. ReefIQ, which MindWalk introduced in June 2026, sits between client discovery data and AI reasoning workflows.
Biology is connected, but drug-discovery data is often fragmented across files, formats, systems, teams, and workflows. ReefIQ reconnects those representations before AI workflows act on them. Sequences, structures, assay outputs, omics, literature, evidence, provenance, and program history become governed, queryable, connected biological context for AI-enabled discovery.
HYFT Technology is MindWalk’s core biological pattern technology, the biological representation foundation with explicit relationships across sequence, structure, function, mechanism, pathway, evidence, and literature. ReefIQ is the client biological context layer built on HYFT. LensAI is the reasoning and application layer. HYFT powers the biological representation. ReefIQ organizes and governs the context. LensAI applies reasoning workflows.
“In life-sciences AI, the durable advantage is not the model a team licenses but the biological context it can reason over. Biology is connected by evolutionary constraint; discovery data arrives fragmented across files and systems, and that gap is where insight is lost. ReefIQ is designed to close it, preserving what every program learns, including the programs that fail, as governed context rather than isolated files. In a regulated setting, that is what makes reasoning trustworthy, and trustworthy is what compounds into the clinic,” said Dr. Jennifer Bath, PhD, CEO and President of MindWalk Holdings Corp.
